TOKYO--(BUSINESS WIRE)--PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a Technology License Agreement with Osaka-based Shionogi & Co., Ltd (“Shionogi”)(TOKYO:4507), to nonexclusively license PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, additional technology access payments, and is eligible to receive payments based on achievement of certain predetermined development milestones for any constrained peptides and/or small molecules discovered from use of the PDPS technology. In addition, PeptiDream is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology.
Similar to the previous 4 technology license agreements, work on peptide-drug conjugates (PDCs) is not included in the non-exclusive license.
PeptiDream will continue to work with Shionogi to identify macrocyclic/constrained peptides against multiple targets of interest selected by Shionogi, and to optimize hit peptides into therapeutic peptides or small molecule products using PeptiDream’s PDPS technology, under the original agreement in February 2016.
[Comment from Kiichi Kubota, CEO of PeptiDream]
“We are
delighted to announce the technology license with Shionogi. Our
R&D collaboration with Shionogi, which started in February 2016, has
already made incredible progress, with the first milestone already
reached in March 2017, and now Shionogi becomes the first Japanese
company to in-license our PDPS technology.
Our proprietary PDPS technology is extremely effective at identifying hit candidates against almost any therapeutic target, even targets against which conventional methods have previously been unsuccessful. We continue to gain experience and knowledge in turning PDPS identified constrained peptide hit candidates into peptide therapeutics and/or small molecule therapeutics, efforts that are greatly accelerated with the information shared and learned across all our collaboration partners and programs.
We strongly hope that this technology license will serve to accelerate the discovery and development efforts at Shionogi, ultimately leading to the identification of novel first-in-class and best-in-class therapeutics to address the world’s unmet medical needs. This technology license is now our 5th and shows that our PDPS technology is becoming a must-have platform for drug discovery worldwide.”
In the past seven years, PeptiDream has established funded discovery collaborations with 17 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, Asahi Kasei, and Janssen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, Lilly, Genentech, and Shionogi.
